
Journal of the American Chemical Society p. 4443 - 4448 (1993)
Update date:2022-08-11
Topics:
Sugiyama, Hiroshi
Tsutsumi, Yasushi
Fujimoto, Kenzo
Saito, Isao
Photoreactions of various 5-iodouracil- (1U)-containing oligonucleotides have been investigated. It was found that d(GCA1UGC)2 undergoes a competitive Cl′ and C2′ oxidation at the 5′ side of the 1U residue to give deoxyribonolactone-containing hexamer 1 and erythrose-containing hexamer 2, respectively. Upon heating under alkaline conditions, erythrose-containing hexamer 2 was shown to undergo a remarkably facile retroaldol reaction to give two fragments, both having phosphoroglycoaldehyde termini in high yields. On the basis of the chemical reactivity of 2, a new specific method for detection of the erythrose-containing sites resulting from deoxyribose C2′ oxidation in DNA was devised. Erythrose-containing sites were prepared by photoirradiation of duplex 1U-containing 13 mer 5′-d(CG1UGT'UTA1UAC 1UG)-3′/5′-d(CAGTATAAACACG)-3′. After photoirradiation, the reaction mixture was treated with hot alkali and NaBH4 and then subjected to enzymatic digestion. HPLC analysis of the digested mixture revealed the formation of modified mononucleotides 25-28, allowing the quantification of the erythrose-containing sites being produced at the 5′ side of all four 1U residues of the 13 mer. These results indicate that this method can be used for the detection and quantification of erythrose-containing sites resulting from deoxyribose C2′ oxidation in DNA.
View More
Contact:+86-25-52346955
Address:199,JIANYE ROAD,NANJING,CHINA
Anhui Gusheng Import&Export CO.,LTD
Contact:86-551-63662296
Address:Jinzhai Road NO.162 ,hefei, china
Contact:+86-371-67759225
Address:No.32, Jinsuo Road, High-tech Zone
Xinchang Yueding Chemical Co., Ltd.
Contact:86-571-56926323
Address:NO.90 BEIMENCHENGWAI CHENGGUAN TOWN XINCHANG
Suzhou Ryan Pharmachem Technology Co.,Ltd
Contact:+86-0512-68780025
Address:B-301,No.2 Taishan Road,Suzhou New District,Jiangsu,P.R. China
Doi:10.1007/BF00961699
(1990)Doi:10.1021/acs.molpharmaceut.6b00466
(2016)Doi:10.1016/j.molliq.2014.06.019
(2014)Doi:10.1016/j.tetlet.2011.07.095
(2011)Doi:10.1021/ja00836a037
(1975)Doi:10.1016/0031-9422(75)85250-2
(1975)